The suspension of trading in the securities of Cann Global Limited (ASX:CGB) is expected to lift and the Company reinstated to official quotation at the commencement of trading on Friday 23 August 2019
Cann Global Limited (ASX:CGB) provides the following update in connection with the reinstatement to quotation of the Company's fully paid Ordinary Shares.
Anatara Lifesciences Ltd's (ASX:ANR) CEO, Steve Lydeamore will be presenting to investors at a Monsoon Communications Twilight Investor Briefing event in Melbourne next week. Investors interested in attending this presentation are invited to reach out.
MMJ (ASX:MMJ) (FRA:2P9) (OTCMKTS:MMJJF) owns a portfolio of minority investments and aims to invest across the full range of emerging cannabis-related sectors including healthcare, technology, infrastructure, logistics, processing, cultivation, equipment and retail.
Cann Global Limited (ASX:CGB) provides the following update in connection with the reinstatement to quotation of the Company's fully paid Ordinary Shares.
Anatara Lifesciences (ASX:ANR) provides an update on the strategic evaluation of Detach(R), its non-antibiotic animal health asset which aids in the control of diarrhoeal disease in piglets (known as scour), with potential application in other livestock animals, aquaculture and companion animals.
As foreshadowed in the Company's announcement dated 15 May 2019, Cann Global Limted (ASX:CGB) confirms that the appointments of David Austin, Jonathan Cohen and John Easterling as independent directors took effect upon approval by Shareholders at the 2 July 2019 General Meeting.
